This is unpublished

Biogen

Active Studies
Actively Enrolling
Transplantation
Pinned
Principal Investigator
Nicolae Leca, MD
Funding Agency
Sponsor: HI-BIO Biogen
Status
Active
Actively Enrolling

Investigator

Nicolae Leca, MD

 

 

 

Nicolae Leca, MD

 

What is the Biogen Study?

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND)

What are the criteria for the study?

Eligible participants must be 18–74 years old, capable of providing informed consent, and have a biopsy-confirmed active or chronic active AMR within 3 months before randomization. 

WHO DO I CONTACT FOR MORE INFORMATION?

Research Coordinator

Nidhi Mehta
E: nidhim3@Nephrology.washington.edu